Literature DB >> 16546970

Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis.

Georges Noël1, Camille Godon, Marie Fernet, Nicole Giocanti, Frédérique Mégnin-Chanet, Vincent Favaudon.   

Abstract

Radiosensitization caused by the poly(ADP-ribose) polymerase (PARP) inhibitor 4-amino-1,8-naphthalimide (ANI) was investigated in 10 asynchronously growing rodent (V79, CHO-Xrs6, CHO-K1, PARP-1+/+ 3T3, and PARP-1-/- 3T3) or human (HeLa, MRC5VI, IMR90, M059J, and M059K) cell lines, either repair proficient or defective in DNA-PK (CHO-Xrs6 and M059J) or PARP-1 (PARP-1-/- 3T3). Pulse exposure to ANI (1-hour contact) potentiated radiation response in rodent cells except in PARP-1(-/-) 3T3 fibroblasts. In contrast, ANI did not significantly enhance radiation susceptibility in asynchronously dividing human cells; yet, single-strand break rejoining was lengthened by ca. 7-fold in all but mouse PARP-1-/- 3T3s. Circumstantial evidence suggested that radiosensitization by ANI occurs in rapidly dividing cells only. Experiments using synchronized HeLa cells consistently showed that ANI-induced radiosensitization is specific of the S phase of the cell cycle and involves stalled replication forks. Under these conditions, prolonged contact with ANI ended in the formation of de novo DNA double-strand breaks hours after irradiation, evoking collision with uncontrolled replication forks of DNA lesions whose repair was impaired by inhibition of the PARP catalytic activity. The data suggest that increased response to radiotherapy by PARP inhibitors may be achieved only in rapidly growing tumors with a high S-phase content.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16546970     DOI: 10.1158/1535-7163.MCT-05-0418

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  44 in total

Review 1.  Targeted therapy in head and neck cancer.

Authors:  S K Kundu; M Nestor
Journal:  Tumour Biol       Date:  2012-02-29

2.  Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.

Authors:  Junko Murai; Shar-Yin N Huang; Amèlie Renaud; Yiping Zhang; Jiuping Ji; Shunichi Takeda; Joel Morris; Beverly Teicher; James H Doroshow; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2013-12-19       Impact factor: 6.261

Review 3.  Targeting DNA repair and the cell cycle in glioblastoma.

Authors:  Brian M Alexander; Nancy Pinnell; Patrick Y Wen; Alan D'Andrea
Journal:  J Neurooncol       Date:  2011-11-24       Impact factor: 4.130

4.  The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation.

Authors:  Celeste Bolin; Mohammed-Tayyib Boudra; Marie Fernet; Laurence Vaslin; Vincent Pennaneach; Tomasz Zaremba; Denis Biard; Fabrice P Cordelières; Vincent Favaudon; Frédérique Mégnin-Chanet; Janet Hall
Journal:  Cell Mol Life Sci       Date:  2011-09-16       Impact factor: 9.261

Review 5.  Organoids as Complex In Vitro Models for Studying Radiation-Induced Cell Recruitment.

Authors:  Benjamin C Hacker; Marjan Rafat
Journal:  Cell Mol Bioeng       Date:  2020-06-15       Impact factor: 2.321

Review 6.  New molecular targets in radiotherapy: DNA damage signalling and repair in targeted and non-targeted cells.

Authors:  Susanne Burdak-Rothkamm; Kevin M Prise
Journal:  Eur J Pharmacol       Date:  2009-10-14       Impact factor: 4.432

Review 7.  Targeting poly(ADP-ribose) polymerase activity for cancer therapy.

Authors:  Frédérique Mégnin-Chanet; Marc A Bollet; Janet Hall
Journal:  Cell Mol Life Sci       Date:  2010-08-20       Impact factor: 9.261

8.  Loss of TRPM2 function protects against irradiation-induced salivary gland dysfunction.

Authors:  Xibao Liu; Ana Cotrim; Leyla Teos; Changyu Zheng; William Swaim; James Mitchell; Yasuo Mori; Indu Ambudkar
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 9.  Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?

Authors:  A Lester; R Rapkins; S Nixdorf; M Khasraw; K McDonald
Journal:  Clin Transl Oncol       Date:  2016-09-21       Impact factor: 3.405

Review 10.  The potential of PARP inhibitors in neuro-oncology.

Authors:  Ross Carruthers; Anthony J Chalmers
Journal:  CNS Oncol       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.